Your browser doesn't support javascript.
Regdanvimab: First Approval.
Syed, Yahiya Y.
  • Syed YY; Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs ; 81(18): 2133-2137, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1491483
ABSTRACT
Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc. for the treatment of coronavirus disease 2019 (COVID-19). In September 2021, regdanvimab received full approval in South Korea for the treatment of COVID-19 in elderly patients aged > 50 years with at least one underlying medical condition (obesity, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients on immunosuppressive agents) and mild symptoms of COVID-19 and in adult patients with moderate symptoms of COVID-19. This article summarizes the milestones in the development of regdanvimab leading to this first approval for COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Immunoglobulin G / Antibodies, Neutralizing / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Drugs Year: 2021 Document Type: Article Affiliation country: S40265-021-01626-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Immunoglobulin G / Antibodies, Neutralizing / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Drugs Year: 2021 Document Type: Article Affiliation country: S40265-021-01626-7